AstraZeneca plc (LSE:AZN; NYSE:AZN) has prioritized six therapeutics to be advanced into Phase III or pivotal testing as fast as possible. Of the six, four are biologics while three are in cancer. Sources: BCIQ: BioCentury Online Intelligence; AstraZeneca's 2013 Investor Day presentation


Product description




Benralizumab (MEDI-563)

mAb against interleukin-5 (IL-5) receptor alpha (IL-5RA; CD125)

Ph IIb for asthma; Ph IIa for chronic obstructive pulmonmary disease (COPD)

Ph IIb data for asthma in 2Q13; Ph IIa data for COPD in 2Q13; Ph III start for asthma in 2H13

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151)